Repligen Corp. (NASDAQ: RGEN) started the day on Wednesday, with a price increase of 4.21% at $167.35, before settling in for the price of $160.59 at the close. Taking a more long-term approach, RGEN posted a 52-week range of $110.45-$211.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 31.42%. Meanwhile, its Annual Earning per share during the time was 15.08%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -17.71%. This publicly-traded company’s shares outstanding now amounts to $55.77 million, simultaneously with a float of $51.96 million. The organization now has a market capitalization sitting at $9.35 billion. At the time of writing, stock’s 50-day Moving Average stood at $136.75, while the 200-day Moving Average is $163.92.
Repligen Corp. (RGEN) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Medical Instruments & Supplies Industry. Repligen Corp.’s current insider ownership accounts for 7.01%, in contrast to 101.95% institutional ownership. According to the most recent insider trade that took place on Jun 14 ’24, this organization’s Chief Executive Officer bought 2,000 shares at the rate of 124.08, making the entire transaction reach 248,160 in total value, affecting insider ownership by 165,177. Preceding that transaction, on Jun 14 ’24, Company’s Director bought 1,615 for 124.94, making the whole transaction’s value amount to 201,776. This particular insider is now the holder of 4,613 in total.
Repligen Corp. (RGEN) Earnings and Revenue Records
Repligen Corp.’s EPS decrease for this current 12-month fiscal period is -17.71% and is forecasted to reach 1.91 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 17.05% through the next 5 years, which can be compared against the 15.08% growth it accomplished over the previous five years trading on the market.
Repligen Corp. (NASDAQ: RGEN) Trading Performance Indicators
Let’s observe the current performance indicators for Repligen Corp. (RGEN). It’s Quick Ratio in the last reported quarter now stands at 5.56. The Stock has managed to achieve an average true range (ATR) of 8.30. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 15.53. Similarly, its price to free cash flow for trailing twelve months is now 78.41.
In the same vein, RGEN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.04, a figure that is expected to reach 0.34 in the next quarter, and analysts are predicting that it will be 1.91 at the market close of one year from today.
Technical Analysis of Repligen Corp. (RGEN)
If we take a close look at the recent performances of Repligen Corp. (NASDAQ: RGEN), its last 5-days Average volume was 1.42 million that shows progress from its year to date volume of 0.64 million. During the previous 9 days, stock’s Stochastic %D was recorded 88.40% While, its Average True Range was 9.40.
Raw Stochastic average of Repligen Corp. (RGEN) in the period of the previous 100 days is set at 60.08%, which indicates a major fall in contrast to 93.24% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 82.37% that was higher than 51.35% volatility it exhibited in the past 100-days period.
